Technical Analysis for RLAY - Relay Therapeutics, Inc.

Grade Last Price % Change Price Change
F 26.68 -3.37% -0.93
RLAY closed down 2.78 percent on Wednesday, May 12, 2021, on 45 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical RLAY trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish -3.37%
New Downtrend Bearish -3.37%
Lower Bollinger Band Walk Weakness -3.37%
Inside Day Range Contraction -3.37%
Oversold Stochastic Weakness -3.37%
Lower Bollinger Band Walk Weakness -6.06%
New 52 Week Low Weakness -6.06%
Lower Bollinger Band Touch Weakness -6.06%
Oversold Stochastic Weakness -6.06%
New 52 Week Closing Low Bearish -3.72%
Older End-of-Day Signals for RLAY ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 2 hours ago
Down 3% about 2 hours ago
Fell Below Lower Bollinger Band about 2 hours ago
New 52 Week Low about 2 hours ago
Down 2 % about 4 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Relay Therapeutics, Inc. Description

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Solid Tumors Drug Discovery Enzymes Precision Medicine Tyrosine Kinase Tyrosine Kinase Receptors Advanced Solid Tumors Fibroblast Growth Factor Fibroblast Growth Factor Receptor Metastatic Solid Tumors Fibroblast Growth Factor Receptor 2

Is RLAY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 64.0
52 Week Low 26.84
Average Volume 729,523
200-Day Moving Average 41.22
50-Day Moving Average 34.64
20-Day Moving Average 31.76
10-Day Moving Average 30.03
Average True Range 2.16
ADX 26.46
+DI 8.68
-DI 27.48
Chandelier Exit (Long, 3 ATRs ) 29.08
Chandelier Exit (Short, 3 ATRs ) 33.33
Upper Bollinger Band 36.19
Lower Bollinger Band 27.33
Percent B (%b) 0.03
BandWidth 27.91
MACD Line -1.97
MACD Signal Line -1.63
MACD Histogram -0.3364
Fundamentals Value
Market Cap 2.48 Billion
Num Shares 90 Million
EPS -0.99
Price-to-Earnings (P/E) Ratio -27.89
Price-to-Sales 0.00
Price-to-Book 6.58
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 30.07
Resistance 3 (R3) 30.33 29.76 29.66
Resistance 2 (R2) 29.76 29.14 29.64 29.52
Resistance 1 (R1) 28.69 28.75 28.41 28.43 29.39
Pivot Point 28.12 28.12 27.98 28.00 28.12
Support 1 (S1) 27.05 27.50 26.77 26.79 25.83
Support 2 (S2) 26.48 27.11 26.36 25.70
Support 3 (S3) 25.41 26.48 25.56
Support 4 (S4) 25.15